Therapeutic Response

BRAF p.V600E status confers therapeutic sensitivity to Dabrafenib in combination with Trametinib in patients with High-Grade Glioma.

Statements

Source and description
Spexotras (trametinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized trametinib in combination with dabrafenib for the treatment of pediatric patients aged 1 year and older with high-grade glioma (HGG) with a BRAF p.V600E variant who have received at least one prior radiation and/or chemotherapy treatment.